The Clinical Utility of Circulating HPV DNA Biomarker in Oropharyngeal, Cervical, Anal, and Skin HPV-Related Cancers: A Review
Human papillomavirus (HPV) is recognized as being related to a wide variety of known cancers: cervical, oropharyngeal, anal, vaginal, penile, and skin. For some of these cancers, rigorous algorithms for screening, therapeutical interventions, and follow-up procedures have been established. Vaccinati...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-07-01
|
| Series: | Pathogens |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-0817/12/7/908 |
| _version_ | 1797587894416703488 |
|---|---|
| author | Ioana Maria Andrioaie Ionut Luchian Costin Dămian Giorgio Nichitean Elena Porumb Andrese Theodor Florin Pantilimonescu Bogdan Trandabăț Liviu Jany Prisacariu Dana Gabriela Budală Daniela Cristina Dimitriu Luminita Smaranda Iancu Ramona Gabriela Ursu |
| author_facet | Ioana Maria Andrioaie Ionut Luchian Costin Dămian Giorgio Nichitean Elena Porumb Andrese Theodor Florin Pantilimonescu Bogdan Trandabăț Liviu Jany Prisacariu Dana Gabriela Budală Daniela Cristina Dimitriu Luminita Smaranda Iancu Ramona Gabriela Ursu |
| author_sort | Ioana Maria Andrioaie |
| collection | DOAJ |
| description | Human papillomavirus (HPV) is recognized as being related to a wide variety of known cancers: cervical, oropharyngeal, anal, vaginal, penile, and skin. For some of these cancers, rigorous algorithms for screening, therapeutical interventions, and follow-up procedures have been established. Vaccination using the nonvalent anti-HPV vaccine, which prevents infection regarding the most frequently involved high-risk HPV types (16, 18, 31, 33, 45, 52, and 58) and low-risk HPV types (6 and 11), has also extensively prevented, controlled, and even eradicated HPV infections. Still, even with all of these multidisciplinary interventions, the burden of HPV cancers is still high worldwide. The circulating DNA of HPV-induced cancers is thought to be an adequate biomarker for optimizing the control of these virus-related cancers. We analyzed the literature published in the last 5 years regarding ctDNA and four of the above-mentioned cancers. The most frequently used assay for ctDNA detection was the droplet digital PCR assay, used for the management of therapy in the late stages of cancer. ctDNA could not be used for early detection in any of the studied cancers. The OPSCCs were the most frequent cancers analyzed via ctDNA assays. Larger, properly designed cohort studies might establish the clinical utility of this biomarker. |
| first_indexed | 2024-03-11T00:45:17Z |
| format | Article |
| id | doaj.art-c7932ac467dc4e1291531b2bfd3cf9a8 |
| institution | Directory Open Access Journal |
| issn | 2076-0817 |
| language | English |
| last_indexed | 2024-03-11T00:45:17Z |
| publishDate | 2023-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pathogens |
| spelling | doaj.art-c7932ac467dc4e1291531b2bfd3cf9a82023-11-18T20:50:44ZengMDPI AGPathogens2076-08172023-07-0112790810.3390/pathogens12070908The Clinical Utility of Circulating HPV DNA Biomarker in Oropharyngeal, Cervical, Anal, and Skin HPV-Related Cancers: A ReviewIoana Maria Andrioaie0Ionut Luchian1Costin Dămian2Giorgio Nichitean3Elena Porumb Andrese4Theodor Florin Pantilimonescu5Bogdan Trandabăț6Liviu Jany Prisacariu7Dana Gabriela Budală8Daniela Cristina Dimitriu9Luminita Smaranda Iancu10Ramona Gabriela Ursu11Department and Preventive Medicine and Interdisciplinarity (IX)—Microbiology, Faculty of Medicine, “Grigore, T. Popa” University of Medicine and Pharmacy, 700115 Iasi, RomaniaDepartment of Periodontology, Faculty of Dental Medicine, “Grigore T. Popa” University of Medicine and Pharmacy, 700115 Iasi, RomaniaDepartment and Preventive Medicine and Interdisciplinarity (IX)—Microbiology, Faculty of Medicine, “Grigore, T. Popa” University of Medicine and Pharmacy, 700115 Iasi, RomaniaDepartment of Periodontology, Faculty of Dental Medicine, “Grigore T. Popa” University of Medicine and Pharmacy, 700115 Iasi, RomaniaDepartment of Medical Specialties (III)—Dermatology, Faculty of Medicine, “Grigore T. Popa” University of Medicine and Pharmacy, 700115 Iasi, RomaniaDepartment of Morpho-Functional Sciences II—Physiology, “Grigore T. Popa” University of Medicine and Pharmacy, 700115 Iasi, RomaniaDepartment of Ortopedy—Traumatology, 700115 Iasi, RomaniaClinical Hospital of Infectious Diseases “Sf. Parascheva”, 700116 Iasi, RomaniaDepartment of Removable Dentures, Faculty of Dental Medicine, “Grigore T. Popa” University of Medicine and Pharmacy, 700115 Iasi, RomaniaDepartment of Biochemistry, “Grigore T. Popa” University of Medicine and Pharmacy, 700115 Iasi, RomaniaDepartment and Preventive Medicine and Interdisciplinarity (IX)—Microbiology, Faculty of Medicine, “Grigore, T. Popa” University of Medicine and Pharmacy, 700115 Iasi, RomaniaDepartment and Preventive Medicine and Interdisciplinarity (IX)—Microbiology, Faculty of Medicine, “Grigore, T. Popa” University of Medicine and Pharmacy, 700115 Iasi, RomaniaHuman papillomavirus (HPV) is recognized as being related to a wide variety of known cancers: cervical, oropharyngeal, anal, vaginal, penile, and skin. For some of these cancers, rigorous algorithms for screening, therapeutical interventions, and follow-up procedures have been established. Vaccination using the nonvalent anti-HPV vaccine, which prevents infection regarding the most frequently involved high-risk HPV types (16, 18, 31, 33, 45, 52, and 58) and low-risk HPV types (6 and 11), has also extensively prevented, controlled, and even eradicated HPV infections. Still, even with all of these multidisciplinary interventions, the burden of HPV cancers is still high worldwide. The circulating DNA of HPV-induced cancers is thought to be an adequate biomarker for optimizing the control of these virus-related cancers. We analyzed the literature published in the last 5 years regarding ctDNA and four of the above-mentioned cancers. The most frequently used assay for ctDNA detection was the droplet digital PCR assay, used for the management of therapy in the late stages of cancer. ctDNA could not be used for early detection in any of the studied cancers. The OPSCCs were the most frequent cancers analyzed via ctDNA assays. Larger, properly designed cohort studies might establish the clinical utility of this biomarker.https://www.mdpi.com/2076-0817/12/7/908biomarkerHPVctDNAearly detectionrelapse |
| spellingShingle | Ioana Maria Andrioaie Ionut Luchian Costin Dămian Giorgio Nichitean Elena Porumb Andrese Theodor Florin Pantilimonescu Bogdan Trandabăț Liviu Jany Prisacariu Dana Gabriela Budală Daniela Cristina Dimitriu Luminita Smaranda Iancu Ramona Gabriela Ursu The Clinical Utility of Circulating HPV DNA Biomarker in Oropharyngeal, Cervical, Anal, and Skin HPV-Related Cancers: A Review Pathogens biomarker HPV ctDNA early detection relapse |
| title | The Clinical Utility of Circulating HPV DNA Biomarker in Oropharyngeal, Cervical, Anal, and Skin HPV-Related Cancers: A Review |
| title_full | The Clinical Utility of Circulating HPV DNA Biomarker in Oropharyngeal, Cervical, Anal, and Skin HPV-Related Cancers: A Review |
| title_fullStr | The Clinical Utility of Circulating HPV DNA Biomarker in Oropharyngeal, Cervical, Anal, and Skin HPV-Related Cancers: A Review |
| title_full_unstemmed | The Clinical Utility of Circulating HPV DNA Biomarker in Oropharyngeal, Cervical, Anal, and Skin HPV-Related Cancers: A Review |
| title_short | The Clinical Utility of Circulating HPV DNA Biomarker in Oropharyngeal, Cervical, Anal, and Skin HPV-Related Cancers: A Review |
| title_sort | clinical utility of circulating hpv dna biomarker in oropharyngeal cervical anal and skin hpv related cancers a review |
| topic | biomarker HPV ctDNA early detection relapse |
| url | https://www.mdpi.com/2076-0817/12/7/908 |
| work_keys_str_mv | AT ioanamariaandrioaie theclinicalutilityofcirculatinghpvdnabiomarkerinoropharyngealcervicalanalandskinhpvrelatedcancersareview AT ionutluchian theclinicalutilityofcirculatinghpvdnabiomarkerinoropharyngealcervicalanalandskinhpvrelatedcancersareview AT costindamian theclinicalutilityofcirculatinghpvdnabiomarkerinoropharyngealcervicalanalandskinhpvrelatedcancersareview AT giorgionichitean theclinicalutilityofcirculatinghpvdnabiomarkerinoropharyngealcervicalanalandskinhpvrelatedcancersareview AT elenaporumbandrese theclinicalutilityofcirculatinghpvdnabiomarkerinoropharyngealcervicalanalandskinhpvrelatedcancersareview AT theodorflorinpantilimonescu theclinicalutilityofcirculatinghpvdnabiomarkerinoropharyngealcervicalanalandskinhpvrelatedcancersareview AT bogdantrandabat theclinicalutilityofcirculatinghpvdnabiomarkerinoropharyngealcervicalanalandskinhpvrelatedcancersareview AT liviujanyprisacariu theclinicalutilityofcirculatinghpvdnabiomarkerinoropharyngealcervicalanalandskinhpvrelatedcancersareview AT danagabrielabudala theclinicalutilityofcirculatinghpvdnabiomarkerinoropharyngealcervicalanalandskinhpvrelatedcancersareview AT danielacristinadimitriu theclinicalutilityofcirculatinghpvdnabiomarkerinoropharyngealcervicalanalandskinhpvrelatedcancersareview AT luminitasmarandaiancu theclinicalutilityofcirculatinghpvdnabiomarkerinoropharyngealcervicalanalandskinhpvrelatedcancersareview AT ramonagabrielaursu theclinicalutilityofcirculatinghpvdnabiomarkerinoropharyngealcervicalanalandskinhpvrelatedcancersareview AT ioanamariaandrioaie clinicalutilityofcirculatinghpvdnabiomarkerinoropharyngealcervicalanalandskinhpvrelatedcancersareview AT ionutluchian clinicalutilityofcirculatinghpvdnabiomarkerinoropharyngealcervicalanalandskinhpvrelatedcancersareview AT costindamian clinicalutilityofcirculatinghpvdnabiomarkerinoropharyngealcervicalanalandskinhpvrelatedcancersareview AT giorgionichitean clinicalutilityofcirculatinghpvdnabiomarkerinoropharyngealcervicalanalandskinhpvrelatedcancersareview AT elenaporumbandrese clinicalutilityofcirculatinghpvdnabiomarkerinoropharyngealcervicalanalandskinhpvrelatedcancersareview AT theodorflorinpantilimonescu clinicalutilityofcirculatinghpvdnabiomarkerinoropharyngealcervicalanalandskinhpvrelatedcancersareview AT bogdantrandabat clinicalutilityofcirculatinghpvdnabiomarkerinoropharyngealcervicalanalandskinhpvrelatedcancersareview AT liviujanyprisacariu clinicalutilityofcirculatinghpvdnabiomarkerinoropharyngealcervicalanalandskinhpvrelatedcancersareview AT danagabrielabudala clinicalutilityofcirculatinghpvdnabiomarkerinoropharyngealcervicalanalandskinhpvrelatedcancersareview AT danielacristinadimitriu clinicalutilityofcirculatinghpvdnabiomarkerinoropharyngealcervicalanalandskinhpvrelatedcancersareview AT luminitasmarandaiancu clinicalutilityofcirculatinghpvdnabiomarkerinoropharyngealcervicalanalandskinhpvrelatedcancersareview AT ramonagabrielaursu clinicalutilityofcirculatinghpvdnabiomarkerinoropharyngealcervicalanalandskinhpvrelatedcancersareview |